Compare FSBW & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | HELP |
|---|---|---|
| Founded | 1936 | N/A |
| Country | United States | Canada |
| Employees | 537 | 50 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.4M | 249.0M |
| IPO Year | 2011 | N/A |
| Metric | FSBW | HELP |
|---|---|---|
| Price | $40.80 | $5.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $46.00 | ★ $51.50 |
| AVG Volume (30 Days) | 8.1K | ★ 638.5K |
| Earning Date | 04-24-2026 | 07-01-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.29 | N/A |
| Revenue | ★ $4,612,000.00 | N/A |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $9.52 | ★ N/A |
| Revenue Growth | ★ 44.80 | N/A |
| 52 Week Low | $36.72 | $4.29 |
| 52 Week High | $44.22 | $8.55 |
| Indicator | FSBW | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 55.08 |
| Support Level | $39.44 | $4.40 |
| Resistance Level | $40.67 | $8.55 |
| Average True Range (ATR) | 1.16 | 0.30 |
| MACD | 0.30 | 0.16 |
| Stochastic Oscillator | 76.21 | 94.85 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.